The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 831-837 , August 2010

Thyroid nodule and thyroid cancer management pre- and post-cardiac transplantation

  • Nicole V. Tilluckdharry, MD

      Affiliations

    • Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Rajan Krishnamani, MD

      Affiliations

    • Cardiac Transplantation Program, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • David DeNofrio, MD

      Affiliations

    • Cardiac Transplantation Program, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Kenneth D. Burman, MD

      Affiliations

    • Endocrine Section, Washington Hospital Center, Washington, District of Columbia
    • ,
  • Caroline S. Kim, MD

      Affiliations

    • Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Caroline S. Kim, MD, Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, 800 Washington St, No. 268, Boston, MA 02111. Telephone: 1-617-636-5689

References 

  1. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas (Prevalence by palpation and ultrasonography). Arch Intern Med. 1994;154:1838–1840
  2. Amedee RG, Dhurandhar NR. Fine-needle aspiration biopsy. Laryngoscope. 2001;111:1551–1557
  3. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:901–911
  4. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411–3417
  5. Hegedus L. Clinical practice (The thyroid nodule). N Engl J Med. 2004;351:1764–1771
  6. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214
  7. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–238
  8. Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer. 2009;16:1065–1072
  9. Kusic Z, Becker DV, Saenger EL, et al. Comparison of technetium-99m and iodine-123 imaging of thyroid nodules: correlation with pathologic findings. J Nucl Med. 1990;31:393–399
  10. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6:34–41
  11. Phillips BD, Hennessey JV. Iodinated contrast prior to evaluation for thyrotoxicosis. J Hosp Med. 2009;4:285–288
  12. Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid. 2001;11:493–500
  13. Brian SR, Cheng DW, Goldberg PA. Unusual case of amiodarone-induced thyrotoxicosis: “illicit” use of a technetium scan to diagnose a transiently toxic thyroid nodule. Endocr Pract. 2007;13:413–416
  14. Morris CN, Tan GH, Smith SA. Amiodarone-induced hyperthyroidism and a thyroid nodule. Endocr Pract. 1998;4:86–88
  15. Cibas ES, Alexander EK, Benson CB, et al. Indications for thyroid FNA and pre-FNA requirements: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:390–399
  16. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid. 1998;8:989–995
  17. Polyzos SA, Anastasilakis AD. Clinical complications following thyroid fine-needle biopsy: a systematic review. Clin Endocrinol (Oxf). 2009;71:157–165
  18. Hor T, Lahiri SW. Bilateral thyroid hematomas after fine-needle aspiration causing acute airway obstruction. Thyroid. 2008;18:567–569
  19. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163:901–908
  20. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J. 2004;147:3–15
  21. Park CH, Byun SS, Kim JH, et al. Arterial bleeding of a thyroid mass after thyroid fine-needle aspiration biopsy: a case report. J Korean Soc Radiol. 2009;60:397–401
  22. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:299S–339S
  23. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med. 2009;76(suppl 4):S37–S44
  24. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63–69
  25. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) (Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons). J Am Coll Cardiol. 2008;52:e1–e142
  26. Veroux M, Giuffrida G, Gagliano M, et al. Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up. Transplant Proc. 2009;41:1142–1144
  27. Pond F, Serpell JW, Webster A. Thyroid cancer in the renal transplant population: epidemiological study. ANZ J Surg. 2005;75:106–109
  28. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612
  29. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–1242
  30. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:525–538, xi
  31. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–791
  32. Baccarani U, Adani GL, Serraino D, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc. 2009;41:1303–1305
  33. Berardinelli L, Messa PG, Pozzoli E, Beretta C, Montagnino G. Malignancies in 2,753 kidney recipients transplanted during a 39-year experience. Transplant Proc. 2009;41:1231–1232
  34. Yagdi T, Sharples L, Tsui S, Large S, Parameshwar J. Malignancy after heart transplantation: analysis of 24-year experience at a single center. J Card Surg. 2009;24:572–579
  35. Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol. 2009;103:562–566
  36. Karamchandani D, Arias-Amaya R, Donaldson N, Gilbert J, Schulte KM. Thyroid cancer and renal transplantation. Endocr Relat Cancer. 2010;17:159–167
  37. Lee J, Jeong JJ, Lee YS, et al. Incidence and clinical behavior of papillary thyroid carcinoma in renal allograft recipients: a single center experience. Transplant Proc. 2008;40:3751–3754
  38. Penn I. Cancers following cyclosporine therapy. Transplantation. 1987;43:32–35
  39. Vegso G, Toth M, Hidvegi M, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007;13:63–69
  40. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997;2:14–17
  41. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant. 2006;25:1024–1042
  42. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74:358–362
  43. Fiorentino M, D'Errico A, Corti B, et al. A multiorgan donor cancer screening protocol: the Italian Emilia-Romagna region experience. Transplantation. 2003;76:1695–1699
  44. Gandhi MJ, Strong DM. Donor derived malignancy following transplantation: a review. Cell Tissue Bank. 2007;8:267–286
  45. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation. 2007;84:272–274
  46. Muiznieks HW, Berg JW, Lawrence W, Randall HT. Suitability of donor kidneys from patients with cancer. Surgery. 1968;64:871–877
  47. Gornicka B, Ziarkiewicz-Wroblewska B, Bogdanska M, et al. Do all well-differentiated thyroid cancers constitute a definite contraindication to obtaining organs for transplantation? (A case report). Transplant Proc. 2003;35:2160–2162
  48. Bhattacharyya N. Apopulation-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg. 2003;128:115–123

PII: S1053-2498(10)00235-4

doi: 10.1016/j.healun.2010.04.003

The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 831-837 , August 2010

Article Tools

* Image Usage & Resolution